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Abstract
Background: Surgeon and patient treatment preferences are important threats to the internal and external validity
of surgical trials such as PROFHER, which compared surgical versus non-surgical treatment for displaced fractures of
the proximal humerus in adults. We explored the treatment preferences expressed by surgeons and patients in the
trial and how these impacted on patient selection, trial conduct and patient outcome.
Methods: A series of exploratory secondary analyses of the PROFHER trial data were undertaken. We reviewed the
extent of surgeon and patient treatment preferences (surgery or not surgery) at screening (n = 1250) as well as prior
preference (including no preference) of randomised patients (n = 250), and assessed their impact on recruitment
and adherence to follow-up and rehabilitation. Changes in treatment after 2 years’ follow-up were explored. Patient
preference and characteristics associated with trial inclusion or treatment preference (t test, chi-squared test,
Wilcoxon rank-sum test) were included as treatment interaction terms in the primary trial analysis of shoulder
functioning (Oxford Shoulder Score, OSS).
Results: Surgeons excluded 17% of otherwise eligible patients based on lack of equipoise; these patients had less
complex fractures (p < 0.001) and tended to be older (p = 0.062). Surgeons were more likely to recommend surgery for
patients under 65 years of age (p = 0.059) and who had injured their right shoulder (p = 0.052). Over half of eligible
patients (56%) did not consent to take part in the trial; these patients tended to be older (p = 0.022), with a preference
for not surgery (74%; which was associated with older age, p = 0.039). There were no differential treatment effects (p
value of interaction) for shoulder functioning (OSS) based on subgroups of patient preference (p = 0.751), age group
(p = 0.264), fracture type (p = 0.954) and shoulder dominance (p = 0.850). Patients who were randomised to their
preferred treatment had better follow-up rates (94 vs 84% at 2 years) and treatment adherence (90 vs 83% reported
completing home exercises). Patients who were not randomised to their preferred treatment were more likely to
change their treatment preference at 24months (60 vs 26%).
Conclusions: The robustness of the PROFHER trial findings was confirmed against possible bias introduced by surgeon
and patient preferences. The importance of collecting preference data is highlighted.
Trial registration: ISRCTN50850043. Registered on 25 March 2008.
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Background
Surgeon and patient treatment preferences are two
major challenges to the success and integrity of ran-
domised controlled trials (RCTs) of surgery, espe-
cially of sharply contrasting interventions where
treatment preferences are typically stronger and
blinding impractical [1, 2]. Both can seriously affect:
trial recruitment, sometimes to the abandonment of
the trial [3]; acceptance of allocated treatment, with
high rates of crossover putting the trial in jeopardy
[4]; adherence to allocated treatments and follow-up;
and outcome assessment [5, 6]. Strong treatment
preferences can seriously impact on both the internal
and external validity of the trial; the second often
reflecting important clinical disparity between the
intended and the actual trial population [7]. Even
where the trial has been completed successfully,
preferences among other factors can still present a
strong barrier to the dissemination and implementa-
tion of trial results [8].
Against this background, detailed preference data were
collected from surgeons and patients at different stages
of the PROximal Fracture of the Humerus Evaluation by
Randomisation (PROFHER) trial. PROFHER was a prag-
matic, multi-centre RCT, funded by the National Insti-
tute for Health Research (NIHR) (UK), that compared
surgical with non-surgical treatment in adults with dis-
placed fractures of the proximal humerus involving the
surgical neck [9, 10]. The protocol target of 250 adults
was recruited between September 2008 and April 2011
from 33 acute care NHS hospitals in the UK. Over 2
years’ follow-up, there was no significant difference be-
tween surgical compared with non-surgical treatment in
patient-reported shoulder functioning (Oxford Shoulder
Score, OSS). PROFHER concluded that the trial’s results
do not support the trend of increased surgery for pa-
tients with these fractures [10, 11]. The direct applicabil-
ity of PROFHER’s findings to current UK practice for
the management of displaced proximal humeral frac-
tures in NHS hospitals was highlighted in recent Na-
tional Institute for Health and Care Excellence (NICE)
guidelines [12].
Surgeons who were not in equipoise with respect to
the study population and trial treatments, as well as pa-
tient preferences for either surgery or not surgery, may
have impacted on the trial in a number of ways. Prefer-
ences may have affected recruitment rate (the trial re-
quired a 13-month extension to recruit its target) and
influenced the selection of patients into the trial, poten-
tially affecting the generalisability of the trial results
(notwithstanding the accepted overall representativeness
of the population evidenced by inclusion in NICE guid-
ance [12]). In addition, prior expectations have the po-
tential to influence outcome assessments at follow-up.
This article therefore explores the evidence for bias
resulting from surgeon and patient treatment prefer-
ences and their impact on the validity of the results in
the PROFHER trial. We discuss our findings in a more
general context of PROFHER and other multi-centre
RCTs comparing surgical and non-surgical treatment in
orthopaedics.
Using data collected from patients and surgeons
throughout the trial, we set out the following research
objectives:
Surgeon preferences
a) To explore to what extent surgeon treatment
preferences affected the selection of eligible patients
into the trial and assess the differences in patient
characteristics between included and excluded
patient populations
b) To explore what patient characteristics were
associated with surgeon preference for surgery and
not surgery for inappropriately excluded patients
Patient preferences
c) To explore to what extent patient treatment
preferences affected patients’ willingness to consent
to taking part in the trial and assess the differences
in patient characteristics between included and
excluded patient populations
d) To explore what patient characteristics were
associated with patient preference for surgery and
for not surgery for non-consenting patients
e) To explore whether patient preferences changed
over the course of the trial
Impact
f) To explore whether treatment preferences at
baseline affected adherence to the trial treatments
and follow-up rates
g) To explore whether patient preferences were
associated with treatment differences for the trial’s
primary outcome
h) To explore whether differences in patient
characteristics associated with preference based
patient exclusion as identified under objectives (a)
to (d) affected treatment differences for the trial’s
primary outcome
Methods
The methods described here pertain to the analysis of
surgeon and patient treatment preferences in the PROF-
HER trial. A full account of the design and methods of
PROFHER is given in the primary trial publication [10].
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Design
This study used data collected as part of the PROFHER
trial to explore the relationships between treatment pref-
erences, patient characteristics and outcome
assessments.
Study population
Adult patients with a displaced fracture of the humerus
involving the surgical neck who were screened for eligi-
bility for inclusion in the PROFHER trial by an ortho-
paedic surgeon in fracture clinics and orthopaedic wards
of 33 hospitals in the UK.
Selection criteria
Well-known limitations for patient selection based on
the Neer classification [13, 14] were accommodated
in PROFHER by using pragmatic inclusion criteria see
(Table 1), with emphasis on the individual surgeon’s
equipoise in terms of whether or not the surgical-
neck fracture should be treated surgically. To counter
learning-curve problems and to maximise the number
of surgeons in equipoise, surgeons were expected to
use surgical interventions and procedures with which
they were familiar. Availability of good quality and
comparable rehabilitation to all trial participants was
ensured [10, 15].
Data collection and outcome measures
Lack of surgeon equipoise was ascertained based on in-
formation provided on the screening form under ‘other
reason to exclude the patient’, following surgeon assess-
ment against the formal trial inclusion/exclusion criteria
(see Table 1). Where patients were excluded from the
trial for such ‘other’ reasons alone, two independent
raters (AR and HH) separately reviewed the reasons pro-
vided and came to a consensus on whether the exclusion
was the result of a lack of surgeon equipoise. This was
conducted as part of ongoing monitoring of recruitment;
with concerns relating to excess lack of equipoise at in-
dividual hospitals being raised with the independent
Trial Steering Committee (TSC) and subsequently with
the hospital’s principal investigator (PI) if advised.
The wording of questions and response options relat-
ing to preferences for either trial treatment are detailed
in Table 2. Surgeon preferences were collected for ex-
cluded patients, whereas surgeons were assumed to be
in equipoise for the patients put forward for randomisa-
tion. For eligible but non-consenting patients, both sur-
geons and patients noted their treatment preferences.
Randomised trial participants were asked for their treat-
ment preferences at baseline and again at the end of the
main trial follow-up at 2 years via the follow-up postal
questionnaire.
Key patient characteristics collected for all patients at
the eligibility assessment were: age, gender, affected
shoulder (left or right), time since injury and tuberosity
involvement (greater and/or lesser tuberosity). Age
group (< 65 years versus ≥ 65 years) and fracture com-
plexity (greater and/or lesser tuberosity versus neither
tuberosity involved) were included as subgroup analyses
in the main trial in line with surgeons’ expectations
(younger patients and more complex fractures were ex-
pected to benefit more from surgery). We hypothesised
that these characteristics may form the basis of prefer-
ences. These groupings were, therefore, included in all
analyses; with age being analysed both as a continuous
and dichotomised outcome.
Follow-up rates were calculated as the number of pa-
tient postal questionnaires returned at 3, 6, 12 and 24
months’ follow-up. Adherence to trial treatment was
quantified as the proportion of patients who crossed
over to the alternative treatment once they had been
randomised, the uptake of physiotherapy and the pa-
tient-reported completion of home exercises. The latter
two were recorded by the physiotherapists as part of the
physiotherapy treatment logs.
Table 1 PROFHER inclusion and exclusion criteria
Inclusion criteria
Adults (aged 16 years or above) presenting within 3 weeks of their injury
with a radiologically confirmed displaced fracture of the humerus
involving the surgical neck
This should include all 2-part surgical-neck fractures; 3-part (including
surgical neck) and 4-part fractures of proximal humerus (Neer
classification). It may also include displaced surgical-neck fractures that
do not meet the exact displacement criteria of the Neer classification (1
cm or/and 45° angulation of displaced parts) where this reflects an
individual surgeon’s equipoise (e.g. whether or not the surgical-neck
fracture should be treated surgically)
Exclusion criteria Number of patients
excludeda
1. Associated dislocation of the injured shoulder
joint
101
2. Open fracture 2
3. Mentally incompetent patient: unable to
understand trial procedure or instructions for
rehabilitation; significant mental impairment that
would preclude compliance with rehabilitation
and treatment advice
116
4. Co-morbidities precluding surgery/anaesthesia 179
5. A clear indication for surgery such as severe
soft-tissue compromise requiring surgery/
emergency treatment (nerve injury/dysfunction)
87
6. Multiple injuries: same limb fractures; other
upper limb fractures
72
7. Pathological fractures (other than osteoporotic) 5
8. Terminal illness 5
9. Participant not resident in trauma-centre
catchment area
28
aMore than one reason per patient possible
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The primary trial outcome was the Oxford Shoulder
Score (OSS; scale 0–48, with higher scores indicating a
better outcome) [16, 17]. It was collected via patient
questionnaires at 6, 12 and 24months. The trial was
powered to detect a clinically important difference in the
OSS of 5 points over 24 months. [9]
Statistical analyses
All analyses were exploratory secondary analyses of the
PROFHER trial data, and statistical tests were not for-
mally powered. Statistical significance was accepted at
the 0.05 level; however, consistent with criteria set for
our subgroup analyses, the level for exploratory identifi-
cation of possible confounding characteristics was set at
p < 0.10. Stata Version 13.1 (StataCorp) was used for all
analyses.
Treatment preferences expressed by surgeons and pa-
tients were tabulated for all patients screened for inclu-
sion in the PROFHER trial, grouped by their eligibility
and consent status. Baseline characteristics (age, gender,
fracture complexity, affected shoulder and days since in-
jury) were summarised for these populations. Compari-
sons were made between patient characteristics for four
patient groups: those classified as being excluded due to
lack of equipoise versus patients assessed as eligible;
non-consenting versus randomised patients; surgeon
preference for surgery versus not surgery among patients
excluded due to lack of equipoise; patient preference for
surgery versus not surgery among non-consenting pa-
tients. Comparisons were conducted using the independ-
ent t test (age), chi-squared tests (gender, age group,
fracture type, affected shoulder) and Wilcoxon rank-sum
test (days since injury). Treatment preferences of rando-
mised patients at baseline and 24months (where
available) were cross-tabulated by allocated treatment
arm and the pattern of change in treatment preferences
described.
Differences in follow-up, crossovers, uptake of physio-
therapy and uptake of home exercises were summarised
for patients who did and did not receive their preferred
treatment. To explore the impact of patient treatment
preferences at baseline on OSS outcome differences, a
preference by treatment interaction term was included
in the primary analysis model, a mixed-effects model of
OSS over 2 years’ follow-up. The model included as fixed
effects: treatment group, time (6 months, 12 months or
24 months), treatment by time interaction, fracture type,
age (< 65 years or ≥ 65 years), gender and health status
(EuroQol five dimensions (EQ-5D) utility score) at base-
line. Time points were nested within patients by means
of an unstructured covariance structure. Any baseline
characteristics that were found to be associated (p <
0.10) with either non-participation in the trial or prefer-
ence for either treatment by surgeons or patients were
included as an interaction term with the randomised
trial treatment to the primary analysis. The interactions
were plotted graphically, and the p values for the inter-
actions reported. We note that analyses for interactions
with age group and fracture type had been conducted as
subgroup analyses of the main trial and are repeated
here if relevant.
Results
Summary of recruitment and follow-up
Of 1250 patients screened, 563 (45%) were assessed as
eligible based on the trial inclusion/exclusion criteria, of
whom 250 (44%) were recruited and randomised. The
rate of treatment crossovers was low: 16 (13%) of 125
patients allocated to surgery were treated non-surgically,
and two (2%) of 125 patients allocated to non-surgical
treatment received surgery. Completed patient question-
naires were obtained from 225 (90%) participants at 3
months, 232 (93%) at 6 months, 225 (90%) at 12 months
and 215 (86%) at 24 months, with comparable return
rates between treatment arms [10, 11].
Surgeon preferences
The review of ‘other’ reasons for exclusion recorded by
surgeons resulted in the identification of 117 patients
(17% of the 687 excluded patients, also 17% of 680
otherwise eligible patients) who were excluded solely be-
cause of a lack of surgeon equipoise. Figure 1 illustrates
their distribution by recruitment site, ordered by recruit-
ment volume. Exclusions because of a lack of equipoise
occurred to a varying extent in 22 centres and not at all
in the remaining 11 centres. The PIs of the two centres
with the highest number of inappropriately excluded pa-
tients (67% and 47% of excluded patients, respectively)
were contacted with the agreement of the TSC and en-
couraged to review the trial protocol with participating
surgeons. In a further notable centre, lack of equipoise
Fig. 1 Lack of surgeon equipoise out of total excluded patients by
centre, ordered by volume
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was the reason for rejecting all of their seven excluded
patients.
Lack of equipoise for one or more patients was re-
corded for 68 (38%) of 178 participating surgeons. Ex-
clusion based on lack of equipoise was more prominent
at some sites (12 of 17 surgeons in one centre) than
others (1 in 16 in another). Twelve surgeons who
showed lack of equipoise only screened and excluded
one patient.
Compared with eligible patients, patients excluded
based on lack of surgeon equipoise tended to be older
(mean age: 69.9 years versus 67.4 years, p = 0.062; 72 vs
60% of age 65 years or over, p = 0.024) and were less
likely to have a fracture involving one or both tuberosi-
ties (59 vs 75%, p < 0.001), see Table 3. Of 99 of these
excluded patients for whom surgeons reported their
advised treatment, 41 (41%) were advised surgery and 58
(59%) not surgery see (Table 2). Surgery was recom-
mended more often for patients under the age of 65
years than ≥ 65 years (57 vs 36%, p = 0.059), and if the
affected shoulder was the right one rather than the left
one (50 vs 31%, p = 0.052), see Table 4. Fracture com-
plexity did not appear to influence surgeon treatment
recommendation (p = 0.794).
Patient preferences
Of 563 eligible patients, 313 (56%) did not consent to
take part in the trial. Compared with consenting pa-
tients, non-consenters tended to be slightly older (mean
age: 68.5 years versus 66.0 years, p = 0.022; however, our
a priori age threshold of 65 years appeared less relevant
to patients: p = 0.114), see Table 3. Fracture severity did
not affect patient preferences (p = 0.272). Of 304 non-
consenting patients who indicated a treatment prefer-
ence, the majority (n = 226, 74%) preferred not surgery,
whereas 55 (18%) preferred surgery and 23 (8%) had no
preference, see Table 2.
Younger patients were more likely to favour surgery
than not surgery (mean of 65.1 years versus 69.2 years,
p = 0.039); however, this was not reflected by patients
being below or above 65 years of age (p = 0.318), see
Table 4. Fracture type in terms of tuberosity involve-
ment did not appear to affect treatment choice to a
significant extent (p = 0.170), although the trend was for
surgery to be preferable for more complex fractures than
less complex ones (44/204; 22 vs 11/77; 14%).
At 24 months’ follow-up, patients who received their
preferred treatment largely retained their baseline pref-
erence, which was stronger for non-surgery (20/28; 71%)
than surgery (12/31; 61%), see Table 5. Patients who did
not receive their preferred treatment were more likely to
change their preference (38/63, 60%) compared with
those who did (18/69, 26%). These patients changed
their preference to their allocated treatment to a similar
extent (38% in the surgery arm and 39% in the non-sur-
gery arm). However, patients with non-preferred alloca-
tion were more likely to retain their original preference
if this was not surgery (8/32; 25% vs 5/31; 16% for sur-
gery). Patients with non-preferred allocation who ini-
tially preferred surgery were more likely to change to no
preference (9/31; 29% vs 5/32; 16% for not surgery). Of
those patients who had no preference at baseline, more
surgery patients preferred their allocated treatment at
24 months (27/52; 52%) compared with not-surgery pa-
tients (22/63; 35%).
Impact of preferences on PROFHER follow-up and
treatment adherence
Overall return rates of patient-completed postal ques-
tionnaires were high; however, patients randomised to
their preferred treatment were more likely to return
questionnaires (97%, 96%, 94% and 94% at 3 months, 6
months, 12 months and 24months, respectively) com-
pared with patients randomised to their non-preferred
treatment (87%, 94%, 90% and 84%) or patients who had
no treatment preferences (87%, 90%, 88% and 84%). Of
the 18 treatment crossovers in the trial, 9 (50%, 8 sur-
gery, 1 non-surgery) could be attributed to patient pref-
erence (reported as change of mind, 8 of these had been
allocated to their non-preferred treatment) and 3 (17%,
2 surgery, 1 non-surgery) could be attributed to surgeon
preferences (change of mind or preference by a different
surgeon). The remaining six (33%) crossovers were pa-
tients given non-surgical treatment after being identified
as unfit for surgery. Patients who were allocated to their
preferred treatment took up the physiotherapy element
of treatment to a similar extent (96% started treatment,
median of eight sessions) compared with patients who
were not allocated to their preferred treatment (95%
started treatment, median of eight sessions) and patients
who had no preference (93% started treatment, median
of 7.5 sessions). Home exercises were self-reported as
being completed by 90%, 84% and 82% of patients who
were allocated to their preferred treatment (total n = 69),
non-preferred treatment (n = 63) and with no preference,
respectively (n = 115).
Impact of preferences on PROFHER primary outcome
OSS outcomes by patient preference at baseline are illus-
trated in Fig. 2. Patients who preferred not surgery gen-
erally had higher OSS scores, indicating greater
functioning, than patients who preferred surgery. How-
ever, there were no treatment-group differences based
on baseline preference (p value of interaction = 0.751). In
terms of characteristics associated with treatment prefer-
ences, age was shown to impact on the selection of trial
patients by surgeons into the trial (older patients were
more likely to be excluded) and to influence treatment
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choice by surgeons and patients (surgery being favoured
for and by younger patients). The PROFHER subgroup
analysis by age group demonstrated, however, that the
pattern of OSS scores following surgical or non-surgical
treatment did not differ for patients above or below 65
years of age (p value of interaction = 0.264), see Fig. 3.
Furthermore, fracture complexity played a role in deci-
sion making for surgeons who were not in equipoise
(fractures involving neither tuberosities being more
likely to be excluded). Again, the subgroup analysis by
fracture type demonstrated that treatment-group
differences in OSS scores did not differ for tuberosity in-
volvement (p value of interaction = 0.954). In addition to
subgroup analyses that had already been conducted, OSS
scores were compared between patients who injured
their dominant and non-dominant shoulder, following
the observation that surgeons not in equipoise were
more likely to recommend surgery when the right shoul-
der was affected. While shoulder dominance was not
collected for excluded patients, the side of injury and
dominance were synonymous for 89% of randomised
participants. Results show that patients who injured their
Table 4 Patient characteristics of patients excluded due to surgeon or patient preferences by preferred treatment
Characteristic Surgeon preference (for patients excluded due to lack of
equipoise, n = 117)
Patient preference (of non-consenting
patients, n = 313)
Surgery Not surgery p value Surgery Not surgery p value
Gender
Male, n (%) 11 (48%) 12 (52%) 0.4761 11 (17%) 55 (83%) 0.4761
Female, n (%) 30 (39%) 46 (61%) 44 (21%) 169 (79%)
Age (years)
N 41 56 53 214
Mean (SD) 68.0 (2.06) 72.4 (1.76) 0.1052 65.1 (15.59) 69.2 (12.21) 0.0392
Median 68.8 75.0 69.3 70.7
< 65 years, n (%) 16 (57%) 12 (43%) 0.0591 23 (23%) 77 (77%) 0.3181
≥ 65 years, n (%) 25 (36%) 44 (64%) 30 (18%) 137 (82%)
Fracture type
One or both tuberosities involved, n (%) 23 (43%) 31 (57%) 0.7941 44 (22%) 160 (78%) 0.1701
Neither tuberosity involved, n 18 (40%) 27 (60%) 11 (14%) 66 (86%)
Affected shoulder
Left, n (%) 15 (31%) 34 (69%) 0.0521 28 (20%) 109 (80%) 0.9531
Right, n (%) 24 (50%) 24 (50%) 27 (20%) 107 (80%)
Days since injury
N 41 58 55 226
Mean (SD) 6.5 (5.83) 4.7 (4.94) 0.2533 5.5 (5.26) 5.2 (4.68) 0.9123
Median 4 2 4 3
1Chi-squared test (df = 1), 2Independent t test, 3Wilcoxon rank-sum test. SD standard deviation
Table 5 Treatment preferences of randomised participants at baseline and 24-month follow-up by treatment allocation
Patient preference at baselinea Randomised allocation (n)
Surgery Not surgery No preference
Patient
preference at
24 months
Surgery Not surgery Surgery Not surgery Surgery Not surgery
(n = 41) (n = 31) (n = 32) (n = 28) (n = 52) (n = 63)
Surgery, n (%) 25 (61%) 5 (16%) 12 (38%) 3 (11%) 27 (52%) 12 (19%)
Not surgery, n (%) 4 (10%) 12 (39%) 8 (25%) 20 (71%) 3 (6%) 22 (35%)
No preference, n (%) 7 (17%) 9 (29%) 5 (16%) 4 (14%) 12 (23%) 17 (27%)
Missing, n (%) 5 (12%) 5 (16%) 7 (22%) 1 (4%) 10 (19%) 12 (19%)
aPatients with missing baseline preferences are excluded from this table (n = 3)
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Fig. 2 Comparison of Oxford Shoulder Score by treatment arm, grouped by patient baseline preferences
Fig. 3 Comparison of Oxford Shoulder Score by treatment arm, by subgroups of age (a), fracture type (b) and shoulder dominance (c)
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dominant shoulder had on average worse outcomes;
however, the differences between surgical and non-surgi-
cal treatment were comparable for dominant and non-
dominant shoulders (p value of interaction = 0.850), see
Fig. 3.
Discussion
Summary of results
In our exploration of the effects of surgeon and patient
treatment preferences on bias and applicability in the
PROFHER trial, we have addressed all of our study ob-
jectives. In terms of surgeon treatment preferences and
with reference to our objectives, we found that (a) 17%
of otherwise eligible patients were excluded because of
lack of surgeon equipoise; and these excluded patients
were on average 2.5 years older and had less complex
fractures (no tuberosity involvement) than eligible pa-
tients and (b) surgeons tended to preferentially recom-
mend surgery for younger patients and patients who had
injured their right shoulder, but that fracture type did
not seem to determine treatment recommendation.
In terms of patient preferences, we found that (c) over
half of otherwise eligible patients (56%) did not consent
to take part in the trial, and non-consenters were on
average 2.5 years older and preferred not surgery (74%);
(d) preference for surgery or not surgery by non-con-
senters was not associated with age or any other baseline
characteristics and (e) at 24 months’ follow-up, similar
proportions of patients switched their treatment prefer-
ence to their allocated treatment in each trial arm; how-
ever, for patients who were not allocated to their
preferred treatment, individuals with a baseline prefer-
ence for surgery were more likely to change to no pref-
erence than patients who preferred not surgery.
Finally, in our examination of the impact of prefer-
ences we found that (f) for patients who were allocated
their preferred treatment slightly better follow-up rates,
fewer patients who changed their mind regarding their
willingness to receive their randomised treatment and
slightly greater engagement with therapeutic elements
such as completing home exercises; (g) in terms of the
PROFHER primary outcome (OSS), that there were no
treatment-group differences based on patient prefer-
ences at baseline and that (h) subgroups based on factors
linked to patient selection or treatment preferences (age,
tuberosity involvement and shoulder dominance) did
not show differential response to surgical and non-surgi-
cal treatment.
The research arena before PROFHER, as for several
other recently undertaken NIHR-funded, substantial
multi-centre RCTs in orthopaedic trauma surgery
research such as DRAFFT [18], was of poor quality, fea-
turing small, often under-recruited RCTs and aborted
trials [9]. Achievement of our recruitment target alone is
an indication of success in meeting the challenges of
surgeon and patient treatment preferences, albeit over a
more extended time period than planned (31 versus 18
months). Other substantive indicators are low crossover
rates, high retention rates and comparable standards in
care including equivalent participation in home exercises
in both treatment groups. The findings of our explora-
tory analyses of the effects of treatment preferences
should be seen in this context.
Surgeon treatment preferences
Although lack of surgeon equipoise is often considered
an influential contributor to poor trial recruitment, we
have found very few estimates in the literature of the ex-
tent of loss of otherwise eligible patients attributed spe-
cifically to this. We note, however, a similar lack of
surgeon equipoise accounted for the loss of 17% of all
potentially eligible patients in the Australasian Laparo-
scopic Colon Cancer Study [19]. Our finding that ex-
cluded eligible patients tended to be older is consistent
with surgery being recommended more often for youn-
ger patients; this reflects current practice and that pa-
tient age has been demonstrated to affect surgeons’
treatment decisions for these fractures [20]. Our examin-
ation of the centre distribution of excluded patients be-
cause of lack of equipoise showed an uneven
distribution, with nearly a third of exclusions from just
two centres and none from 11 centres. The potential of
centre-specific effects is countered by the confirmation
of no statistically significant treatment difference follow-
ing adjustment for clustering by centre in a sensitivity
analysis of the primary outcome [11]. The finding that
68 of 178 surgeons in PROFHER excluded one or more
otherwise eligible patients due to lack of equipoise is
concerning in terms of the perceived applicability of the
trial results. Ziebland et al. in the Spine Stabilisation
Trial reported the underlining lack of understanding of
the study inclusion criteria and design by such surgeons
could lead to a reluctance to apply the results to their
own practice [21]. Nonetheless, the PROFHER trial
population has been independently assessed as represen-
tative of current UK practice [12], and the results of a
survey of 265 orthopaedic shoulder surgeons in 2016
demonstrated notable changes in UK practice in line
with, and because of, PROFHER findings [22].
Patient treatment preferences
Nearly three quarters (72%) of non-consenting patients
preferred not surgery, with only 7% having no prefer-
ence. In contrast, slightly more consenting patients pre-
ferred surgery (29%) than non-surgery (24%), and almost
half (46%) had no treatment preference at baseline.
These findings are consistent with our expectations for
this patient group, both in terms of a general preference
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for not surgery and also a greater proportion of patients
with no preference among those willing to be rando-
mised. The involvement of impartial research nurses or
physiotherapists, rather than the treating surgeons, at
the consent phase may well have contributed to the lack
of treatment preference, as did the training providing by
the trial team and development of a patient information
leaflet with patient representative input. We note that
retention and adherence to the trial treatments were
already high in PROFHER and balanced between treat-
ment arms. Although the differences observed here were
in line with previous findings, which tended to show that
those without a treatment preference had the lowest re-
sponse rates during follow-up [5], we note that they
were of small magnitude in terms of patient numbers
with little scope to impact on the study results. Crucially,
patient treatment preferences did not significantly affect
patients’ treatment outcome with regard to the main
OSS findings.
Limitations
As noted in our methods, all statistical tests were not
formally powered; however, there were no emerging
trends for preference-based treatment differences. While
our study adjusted the trial analysis for differences in the
composition of included and excluded patient popula-
tions based on preferences in order to confirm the exter-
nal validity of the PROFHER findings, we acknowledge
that populations may have differed in other unknown as-
pects that we could not control for. However, we note
that we included major a priori determinants of patient
selection such as age and fracture complexity.
Potential anomalies can arise from the use of artificial
thresholds for continuous outcomes. Our selection of
the 65-year age boundary is one that reflects a com-
monly perceived threshold for older people by clinicians
that was likely to form part of their decision making. It
is not surprising that patients were less influenced by
this cut-off, as this was unlikely to be part of their con-
siderations. Also notable is that readiness or acceptabil-
ity for surgery is likely to be condition dependent; the
design of a trial investigating anterior cruciate ligament
reconstruction surgery reflected the strong preferences
in younger patients for surgery [23].
At the time of finalising our trial design, we accepted
our funder’s instruction and guidance not to perform a
comprehensive cohort design as it was likely to distract
from RCT recruitment nor to undertake a qualitative
study to explore patients’ reasons for non-participation
in the trial. (We also accepted Ethics Committee guid-
ance not to ask non-consenting patients for their reasons
for non-participation.). These methods have provided
useful insights on treatment preferences in other areas
[19, 24, 25]. However, as shown by our paper, our
systematic approach is feasible, has provided valuable in-
sights and, we suggest, is one suitable for wider
adoption.
Conclusions
Although PROFHER recruited to target, the need for a
recruitment extension was, in part, the result of the pref-
erences held by surgeons (lack of equipoise) and patients
(lack of consent). A systematic multicomponent explor-
ation of the extent and impact of surgeon and patient
preferences revealed a consistent picture, primarily
where preferences for not surgery by surgeons and pa-
tients alike were associated with older patient age, which
led to slightly younger patients being recruited into the
trial. Secondary analyses showed that neither surgeon
nor patient treatment preferences importantly affected
internal validity (differences in dropout and adherence
were of small magnitude in light of the overwhelmingly
high follow-up and engagement with the interventions
in PROFHER) nor external validity (no meaningful treat-
ment differences for predictors of patient selection, in-
cluding age, and treatment preferences). Independent
corroboration of the external validity of the trial findings
was via the inclusion of these in national guidance
(NICE) as well as separate evidence of acceptance of trial
findings by specialist UK surgeons. Ongoing monitoring
of the lack of equipoise at sites helped to manage sur-
geon bias in the trial, and the collection of data pre-
sented here proved invaluable in evaluating the validity
of the trial results.
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